Scrutinizer Report of Shareholders Meeting of the company held on 29th September 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bacil Pharma Ltd held its 38th Annual General Meeting on September 29, 2025 at 1:00 PM via video conferencing. The scrutinizer, M/s Ramesh Chandra Bagdi & Associates, submitted the consolidated report on remote e-voting and e-voting during the AGM. A total of 49 members cast 40,06,227 votes out of 1,49,90,200 outstanding shares, representing just 26.72% voting participation. All 10 resolutions were passed with 100% votes in favour and zero votes against. Key resolutions included adoption of FY25 audited financial statements, re-appointment of Ms. Chaitali Kalpataru Shah as Executive Director, appointment of a new Independent Director (Ms. Vivek Mukesh Yadav), appointment of new statutory auditors (M/s Sarang Shivajirao Chavan & Associates) to fill a casual vacancy, and approval of enhanced borrowing limits and fund-raising authority including loans convertible into equity.
All resolutions passed unanimously, indicating shareholder support, though the low 26.72% turnout means a small base of shareholders drove the outcome. The change in statutory auditors and the fresh approvals for borrowing and equity-linked fund raising could signal upcoming capital activity or restructuring worth monitoring.